Serum Vascular Endothelial Growth Factor in Epithelial Ovarian Neoplasms: Correlation with Patient Survival

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

“…Log-rank test was used to evaluate the differences in progression-free survival (p=0.161) and overall survival (p=0.366) distributions by low versus high VEGF. untreated primary EOC [18][19][20][21][22][23][24], and to test the hypothesis that elevated VEGF levels in association with a rising CA-125 may herald a particularly aggressive recurrent tumor that might benefit from early intervention with agents that have anti-angiogenic properties like thalidomide [12] or tamoxifen [6,11], or be associated with thalidomide-resistance and production of pro-angiogenic cytokines during thalidomide treatment as observed in relapsing and resistant multiple myeloma [30]. In GOG#198, neither pre-treatment VEGF nor changes in VEGF concentration (pre-and post-treatment) were associated with PFS, OS or treatment.…”

“…Translational objectives were to determine whether changes in VEGF in serum were independent of randomization treatment, or associated with PFS. VEGF is a potent proangiogenic factor [17] with prognostic value in primary EOC [18][19][20][21][22][23][24]. Its value in recurrent EOC is not well understood [25][26][27][28][29].…”

Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts

“…Recently, enzyme-linked immunosorbent assay (ELISA) allows quantitative determination of VEGF in the serum of patients with various histologic types of cancer [11,13,15,[18][19][20][21][22][23][24][25][26][27]. High serum VEGF levels were associated with poor survival in non-Hodgkin's lymphoma, renal cell carcinoma, ovarian cancer, and vulvar cancer [21,23,26,27]. The levels of VEGF in the serum of lung cancer patients have been evaluated by a few studies, and one report suggested the prognostic significance of elevated VEGF in small cell lung cancer patients [15,18,22,24,25].…”

Quantification of VEGF mRNA Expression in Non-Small Cell Lung Cancer Using a Real-Time Quantitative Reverse Transcription-PCR Assay and a Comparison with Quantitative Competitive Reverse Transcription-PCR

“…At the protein level, immunohistochemical staining (IHC) has been used for semiquantitative analysis of VEGF expression (Fontanini et al, 1997) and ELISA has been used to quantify cytosolic VEGF protein expression (Chen et al, 1999). At the transcriptional level, Northern blots and polymerase chain reaction (PCR)-based quantitative methods have been used to assess VEGF mRNA expression in tissues (Gu et al, 1999).…”